RRPV #TACTIC_Pre-Solicitation-Notice

BARDA Pre-Solicitation for Threat-Agnostic CBRN Therapeutics Development

This opportunity is a pre-solicitation from the Biomedical Advanced Research and Development Authority (BARDA), under the U.S. Department of Health and Human Services, seeking development of medical countermeasures (MCMs) for CBRN (chemical, biological, radiological, and nuclear) threats. - Government Buyer: - Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health and Human Services - OEMs and Vendors: - No specific OEMs or vendors named; open to all RRPV Consortium members and potential new members - Products/Services Requested: - Development of threat-agnostic therapeutics targeting host-dysregulation from CBRN threats - Focus on products effective in delayed treatment settings and with broad applicability (e.g., viral hemorrhagic fevers, radiation exposure, chemical injuries) - Includes design, manufacturing, and nonclinical testing performed in the U.S. - Unique or Notable Requirements: - Multistage competitive proposal process - Mandatory RRPV Consortium membership for offerors - Out-of-scope: vaccines and prophylactic-only products - Anticipated funding of approximately $15 million, with 2-3 awards - Period of performance up to five years

Description

This pre-solicitation notice from BARDA seeks to support the development of medical countermeasures (MCMs) that treat host-dysregulation caused by chemical, biological, radiological, and nuclear (CBRN) threats. The therapeutics should be threat-agnostic, effective in delayed treatment settings, and target host responses rather than specific agents. The effort aims to address gaps where agent-specific therapeutics are limited, focusing on broad applicability across multiple CBRN threat categories. The anticipated funding is approximately $15 million with 2-3 awards expected, and the period of performance is up to five years.

View original listing